Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
FREE SEO Check & Google Maps Check for Sri Lankan Businesses | Web Design, Website Price Rs 14,900 |
LankaSolve
Updated:
Yesterday at 7:01 PM
ඕනම රටකට සෙට් වෙන CV එකක්
ErMurazor
Updated:
Saturday at 9:50 AM
Hambantota
7 Acres Beachfront Land For Sell DownSouth , PerPerch Price 420 000
1024 Digital
Updated:
Oct 14, 2026
Baseus PI LITE INDOOR CAMERA
ErMurazor
Updated:
Oct 12, 2026
Ad icon
Colombo
Hard Disk For Sale
mazza
Updated:
Oct 10, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
ElaKiri.com
News and Updates
Real World data - Impaired immune response - with chronic conditions
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 26738008" data-attributes="member: 562115"><p>A recent study done in the US shows that <strong>mRNA vaccine antibody response is impaired </strong>in those with chronic medical conditions. (Note: In the US it was Pfizer & Moderna mRNA vaccines used and hence the study is on those) The study was done in a pulmonary specialty outpatient clinic, Colorado.</p><p></p><p>This raises concerns that SARS-CoV-2 vaccination may <strong>not result</strong> in protective immunity in<strong> all populations</strong> and may have implications for some as masking and distancing strategies are abandoned.</p><p></p><p>In this study with 226 outpatients, 79% of the patients had chronic pulmonary diseases and <strong>26% of them had no antibody detected over 14 days after the second dose of mRNA vaccines</strong>.</p><p></p><p>Also they found that<strong> interstitial lung disease (ILD) is an independent risk factor</strong> for reduced antibody response. Additionally CHF (Congstive Heart Failure) and some biologic/JAK inhibitor use (particularly rituximab) are independent risk factors for decreased antibody response. The effect of rituximab use is<strong> consistent</strong> with a previous study too.</p><p>BUT <strong>no significant effects on antibody response</strong> were observed with <strong>other medications</strong> including systemic/inhaled corticosteroids, and other immunosuppressants including methotrexate, mycophenolate mofetil, azathioprine, leflunomide, cyclosporine, tacrolimus, mycophenolic acid, sirolimus, and everolimus.</p><p></p><p>While the exact antibody level that confers protection against SARS-CoV-2 is unknown and there are other markers of B cell and T cell-mediated protection. </p><p>They report that further studies of immunologic response (including neutralizing antibodies and other markers of B cell and T cell response) and protection in vulnerable populations are needed to define ongoing COVID-19 risk and inform recommendations regarding additional vaccination and behaviors to mitigate risk.</p><p></p><p>[ATTACH=full]138512[/ATTACH]</p><p></p><p><em>Multivariate logistic regression of the association between antibody response and clinical characteristics. OR: odds ratio; CI: confidence interval; COPD: chronic obstructive pulmonary disease; ACE/ARB: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers. *Biologics: Anti- IL-5, -IL-6, -IL-12/23, -IL-17, -IgE, -CD20, and -TNF-α inhibitors †BNT162b2 (Pfizer-BioNTech) compared to mRNA-1273 (Moderna) ‡Days after 2nd vaccine dose.</em></p></blockquote><p></p>
[QUOTE="imhotep, post: 26738008, member: 562115"] A recent study done in the US shows that [B]mRNA vaccine antibody response is impaired [/B]in those with chronic medical conditions. (Note: In the US it was Pfizer & Moderna mRNA vaccines used and hence the study is on those) The study was done in a pulmonary specialty outpatient clinic, Colorado. This raises concerns that SARS-CoV-2 vaccination may [B]not result[/B] in protective immunity in[B] all populations[/B] and may have implications for some as masking and distancing strategies are abandoned. In this study with 226 outpatients, 79% of the patients had chronic pulmonary diseases and [B]26% of them had no antibody detected over 14 days after the second dose of mRNA vaccines[/B]. Also they found that[B] interstitial lung disease (ILD) is an independent risk factor[/B] for reduced antibody response. Additionally CHF (Congstive Heart Failure) and some biologic/JAK inhibitor use (particularly rituximab) are independent risk factors for decreased antibody response. The effect of rituximab use is[B] consistent[/B] with a previous study too. BUT [B]no significant effects on antibody response[/B] were observed with [B]other medications[/B] including systemic/inhaled corticosteroids, and other immunosuppressants including methotrexate, mycophenolate mofetil, azathioprine, leflunomide, cyclosporine, tacrolimus, mycophenolic acid, sirolimus, and everolimus. While the exact antibody level that confers protection against SARS-CoV-2 is unknown and there are other markers of B cell and T cell-mediated protection. They report that further studies of immunologic response (including neutralizing antibodies and other markers of B cell and T cell response) and protection in vulnerable populations are needed to define ongoing COVID-19 risk and inform recommendations regarding additional vaccination and behaviors to mitigate risk. [ATTACH type="full"]138512[/ATTACH] [I]Multivariate logistic regression of the association between antibody response and clinical characteristics. OR: odds ratio; CI: confidence interval; COPD: chronic obstructive pulmonary disease; ACE/ARB: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers. *Biologics: Anti- IL-5, -IL-6, -IL-12/23, -IL-17, -IgE, -CD20, and -TNF-α inhibitors †BNT162b2 (Pfizer-BioNTech) compared to mRNA-1273 (Moderna) ‡Days after 2nd vaccine dose.[/I] [/QUOTE]
Insert quotes…
Verification
Hath warak paha keeyada? (hatha wadikireema paha)
Post reply
Top
Bottom